Publications by authors named "Sunil Arani Reddy"
Our purpose was to investigate the prognostic value of F-FDG PET/CT parameters in melanoma patients before beginning therapy with antibodies to the programmed cell death 1 receptor (anti-PD-1). Imaging parameters including SUV, metabolic tumor volume, and the ratio of bone marrow to liver SUV (BLR) were measured from baseline PET/CT in 92 patients before the start of anti-PD-1 therapy. The association with survival and imaging parameters combined with clinical factors was evaluated.
View Article and Find Full Text PDFPurpose: We investigated the ability of baseline 2-deoxy-2-[F]fluoro-D-glucose PET/CT parameters, acquired before the start of immunotherapy, to predict development of hyperprogressive disease (HPD) in melanoma patients. We also evaluated the diagnostic performances of ratios of baseline and first restaging PET/CT parameters to diagnose HPD without information of the tumor growth kinetic ratio (TGKR) that requires pre-baseline imaging before baseline imaging (3 timepoint imaging).
Procedures: Seventy-six patients who underwent PET/CT before and approximately 3 months following initiation of immunotherapy were included.
Purpose: The purpose of this study was to investigate the prognostic value of whole-body metabolic tumor volume (MTV) and other metabolic tumor parameters, obtained from baseline and first restaging F-FDG PET/CT scans in melanoma patients treated with immune checkpoint inhibitors (ICIs).
Methods: Eighty-five consecutive melanoma patients (M, 57; F, 28) treated with ICIs who underwent PET/CT scans before and approximately 3 months after the start of immunotherapy were retrospectively enrolled. Metabolic tumor parameters including MTV for all melanoma lesions were measured on each scan.